Phase 1, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol

Next Previous
Trial Profile

Phase 1, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Tuberculosis DNA vaccine Ag85A (Primary) ; Tuberculosis DNA vaccine Ag85A
  • Indications Tuberculosis
  • Focus Adverse reactions

    • Most Recent Events

    • 06 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 29 May 2017 Planned primary completion date changed from 30 Apr 2017 to 31 Dec 2019.
    • 29 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top